Abstract
he long-term outcomes of cellular cardiomyoplasty in patients with ischemic cardiac dysfunction were studied. The results of treatment of 45 patients aged 46–70 years, mean age is (56.8±19.7) years, who were hospitalized in the Emergency and Reconstmctive Cardiac Surgery Department of the "V.K. Gusak Institute of Emergency and Reconstmctive Surgery of NAMS of Ukraine" from 2007 to 2013 were analyzed. It was established that the transplantation of autologous mesenchymal bone marrow stem cells using the navigation system is a safe and effective procedure, that helps to increase the survival rates up to 35 (18–61) months compared to 12 (0.72-50.0) months in the group of pharmacological therapy (p value = 0.033). Also the reduction of mortality 36 months after the stem cells injection to 13.3% compared to 46.7% in the group of pharmacological treatment in the same terms was observed. To achieve the maximum effect of treatment, it is reasonable to repeat the procedure of autologous mesenchymal bone marrow stem cells transplantation 1 year later after the first procedure. Endomyocardial implantation of autologous mesenchymal bone marrow stem cells improves basic dimensions of life quality: physical functioning, pain intensity, usual activity and social functioning regardless of the initial severity of ischemic dysfunction. Keywords: stem cells, cardiomyoplasty, heart failure, refractory angina.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
